KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Beginning Cash BalanceCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Cash from Investing Activities: 2011-2022

Historic Cash from Investing Activities for TherapeuticsMD (TXMD) over the last 12 years, with Dec 2022 value amounting to -$74,000.

  • TherapeuticsMD's Cash from Investing Activities rose 95.11% to -$74,000 in Q4 2022 from the same period last year, while for Dec 2022 it was -$355,000, marking a year-over-year increase of 84.03%. This contributed to the annual value of -$355,000 for FY2022, which is 84.03% up from last year.
  • Latest data reveals that TherapeuticsMD reported Cash from Investing Activities of -$74,000 as of Q4 2022, which was down 1,157.14% from $7,000 recorded in Q3 2022.
  • In the past 5 years, TherapeuticsMD's Cash from Investing Activities registered a high of $7,000 during Q3 2022, and its lowest value of -$20.7 million during Q4 2019.
  • Moreover, its 3-year median value for Cash from Investing Activities was -$237,000 (2020), whereas its average is -$348,000.
  • In the last 5 years, TherapeuticsMD's Cash from Investing Activities plummeted by 28,077.04% in 2018 and then skyrocketed by 103.85% in 2022.
  • TherapeuticsMD's Cash from Investing Activities (Quarterly) stood at -$671,171 in 2018, then crashed by 2,986.19% to -$20.7 million in 2019, then surged by 97.62% to -$494,000 in 2020, then slumped by 206.48% to -$1.5 million in 2021, then soared by 95.11% to -$74,000 in 2022.
  • Its Cash from Investing Activities stands at -$74,000 for Q4 2022, versus $7,000 for Q3 2022 and -$76,000 for Q2 2022.